ClinicalTrials.gg
RecruitingNCT02437396Updated Nov 4, 2026

Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease

An observational study in Gaucher Disease Type I, Oxidative Stress and Inflammation, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Minnesota · Observational

How we know

From the registry’s dates

  • Started Oct 2015; still recruiting 11 years 1 month later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
34
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Gaucher Disease with a site in United States — 20 open to participants now, 27 under way, 2 of them phase 3. Gaucher Disease · United States.

Planned enrollment
26th of 39
34 · median 60
Started
2015
with 6 others
Observational
39 of 92
16 open now
Primary completion
2026-12
later than 6 of 25 live
Registered
48th of 92
by date
Lead sponsor
6 of 92
University of Minnesota

Among the 92 studies in Gaucher Disease with a site in United States, this one is the 26th largest by planned enrollment of the 39 observational ones that give a count, is one of 7 that started in 2015, is one of 39 observational ones, reaches primary completion later than 6 of the 25 other live ones, and was the 48th registered.

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

Browse Gaucher Disease studies →

Open to participants now

20 of the 92 studies in Gaucher Disease with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Gaucher Disease with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate oxidative stress and/or inflammation in patients with Gaucher disease type I using a series of biomarkers and correlate with measurements of currently used diagnostic biomarkers.

Read the detailed description

We will determine oxidative stress and/or inflammation related biomarkers in whole blood and/or plasma in adult subjects with Gaucher disease. Fifteen milliliter blood sample will be collected during three independent visits over a period of approximately 3 months. These samples will be processed to separate plasma from red blood cells and frozen until assays are performed. Standardized immunoassay methods and LC/MS based methods will be adopted to assay a series of biomarkers in these samples. These data will be correlated with currently used diagnostic biomarkers.

03

Conditions studied

  • Gaucher Disease Type I
  • Oxidative Stress
  • Inflammation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Type 1 Gaucher disease subjects who are either naive to treatment or are stable on therapy (specific Enzyme Replacement Therapy (ERT) / Substrate Reduction Therapy (SRT) formulation at a specific dose) for at least 2 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All participants must be 18 years or older.
  2. All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written .
  3. Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator.
  4. GD subjects must be stable on a specific ERT and/or SRT therapy at a specific dose (for e.g. on a units/kg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years).
  5. GD1 patients, who have had a change in therapy i.e. a change in dose or switch from one drug to another, can be enrolled after at least 6 months have elapsed since the change and is considered stable in the opinion of the clinician providing care to the patient.
  6. All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.

Exclusion criteria

Exclusion Criteria:

  1. Medically unstable conditions in any group as determined by the investigators
  2. Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study.
  3. Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of
  4. History of asthma that is presently being treated
  5. Subjects who cannot or are unwilling to have blood drawn
  6. Unable to adhere to study protocol for whatever reason
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
34 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Treatment naive GD1

    Type 1 Gaucher disease subjects who are naive to any treatment

  • Treated GD1

    Type 1 Gaucher disease who are stable on therapy (on the specific ERT and/or SRT and specific dose for at least 2 years)

  • Healthy Volunteers (No longer recruiting)

    Age matched healthy controls. No new participants will be enrolled to this arm.

06

What researchers measure

Primary outcomes

  1. Change in Plasma C5a Concentration

    Outcome will be reported as the change in plasma concentration of C5a (ng/ml) from baseline to 6 months in participants with Gaucher disease type 1

    Time frame: 6 months

  2. Change in Plasma Hepcidin Concentration

    Outcome will be reported as the change in plasma concentration of hepcidin (ng/ml) from baseline to 6 months in participants with Gaucher disease type 1

    Time frame: 6 months

Secondary outcomes

  1. Change in Blood Glutathione Concentration

    Outcome will be reported as the change in blood concentration of glutathione (umol/g) from baseline to 6 months in participants with Gaucher disease type 1

    Time frame: 6 months

  2. Change in Plasma Tumor Necrosis Factor (TNF)-alpha Concentration

    Outcome will be reported as the change in blood concentration of TNF-alpha (pg/ml) from baseline to 6 months in participants with Gaucher disease type 1

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2015 (actual). Primary completion is estimated for Dec 2026, 134 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2015
First posted
May 7, 2015
StartActual
Oct 2015
Primary completionEst.
Dec 31, 2026was Oct 2026
CompletionEst.
Dec 31, 2026was Oct 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 30, 2026→Dec 31, 2026
Nov 4, 2026
Study completion
Oct 30, 2026→Dec 31, 2026
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Oct 30, 2026→Dec 31, 2026
    Study completion Oct 30, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02437396
Responsible party
Sponsor
First posted
May 7, 2015
Start date
Oct 2015
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 4, 2026

Study contacts

Reena Kartha, PhD
Contact
rvkartha@umn.edu
612-626-2436
Reena Kartha, PhD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion